Screener
Relmada Therapeutics, Inc. RLMD Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Other income: | ||
| Interest/investment income, net | 959,762 | 440,287 |
| Realized (loss)/gain on short-term investments | (9,867) | 62,952 |
| Unrealized (loss)/gain on short-term investments | (540,097) | 155,731 |
| Total other income, net | 409,798 | 658,970 |
| Net loss | $(19,051,956) | $(17,559,465) |
| Loss per common share – basic and diluted | $(0.22) | $(0.58) |
| Weighted average number of common shares outstanding – basic and diluted | 86,596,873 | 30,408,890 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s shares (diluted)?
- Relmada Therapeutics, Inc. (RLMD) reported shares (diluted) of 86.6M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Relmada Therapeutics, Inc.'s shares (diluted) increased by 184.8% year-over-year, from 30.4M to 86.6M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s shares (diluted) has grown at a 18.7% compound annual growth rate (CAGR), from 68.7M to 136.3M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Relmada Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude